Lipigon Pharmaceuticals AB announced it has completed another safety study with the drug candidate Lipisense yielding positive results. The reported study aimed to investigate cardiovascular safety and focused on identifying any specific effects on the heart and blood vessels. The results show that Lipisense was well tolerated in high doses and did not cause any serious effect on the studied parameters.

Together with the other preclinical safety studies, these data will form the basis for a clinical trial application that is expected to be submitted in the first quarter of 2022. Lipisense is a drug candidate for the treatment of diseases with abnormal levels of lipids in the blood, primarily triglycerides, and a first-in-class treatment with a unique mechanism of action. Elevated triglycerides are a risk factor present in several diseases and Lipisense has the potential to normalize triglyceride levels.

The large population of patients with elevated triglycerides is heterogeneous-- comprising patients with rare genetic disorders to large patient groups, such as type 2 diabetics.